Table 1 Fine Specificity of antibody elicited by SS with CS peptide in Aldara or Addavax with or without TLR agonists.

From: Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunity

SS Adjuvant Composition

Anti-Repeat Antibody

Delivery vehicle

TLR agonist

GMT a (range)

ug/mlb

Fine Specificityc

IgG2c/IgG1 Ratiod

Affinitye [M]

CSPf Titer

Minor

Major

Aldara

TLR 7 imiquimod

142,631 (81,920–327,640)

413

163,840

40,960

0.967

0.625

80

Addavax

none

20,480 (5,120–40,960)

55

20,480

5,120

0.022

0.625

40

Addavax

TLR 7/8 resiquimod

124,168 (81,920–327,640)

250

81,920

40,960

1.117

0.938

40

Addavax

TLR 9 CpG

47,044 (20,480–81,920)

101

40,960

5,120

0.698

0.469

40

Addavax

TLR 7/8 resiquimod + TLR 9 CpG

142,631 (81,920–327,640)

256

81,920

40,960

1.217

0.469

80

  1. aELISA geometric mean titer (GMT) and range of endpoints in individual serum (5 mice/group) obtained post fourth SS immunization.
  2. bTotal μg/ml of anti-repeat antibody in pooled serum calculated based on MAB 2A10 standard.
  3. cELISA plates coated with peptide representing the CS minor 5’repeat region (DPNANPNV)2 or CS major repeat region (NANP)3.
  4. dRatio of IgG2c/IgG1 anti-repeat antibody OD in pooled serum (1:2560 dilution).
  5. eAntibody affinity as measured by molar concentration of NH4SCN required to elute 50% of anti-repeat antibody in ELISA.
  6. fEndpoint dilution of pooled serum giving positive Circumsporozoite Precipitin (CSP) reaction with viable PfPb sporozoites.
Back to article page